Tyrosine phosphatase SHP-1 acts at different stages of development to regulate hematopoiesis

Blood

Volumn 105, Issue 11, 2005, Pages 4290-4297

  Paling, Nicholas R D ^a   Welham, Melanie J ^a  

^a University of Bath   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN SH2; PROTEIN TYROSINE PHOSPHATASE; PROTEIN TYROSINE PHOSPHATASE 1; PROTEIN TYROSINE PHOSPHATASE SHP 2; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BONE MARROW CELL; CELL MATURATION; COCULTURE; COLONY FORMATION; CONTROLLED STUDY; EMBRYONIC STEM CELL; GRANULOCYTE; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; IMMUNE SYSTEM; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 19344362869     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2004-08-3271     Document Type: Article

References (49)

1. Matthews RJ, Bowne DB, Flores E, Thomas ML. Characterization of hematopoietic intracellular protein tyrosine phosphatases: description of a phosphatase containing an SH2 domain and another enriched in proline-rich, glutamic acid-rich, serine-rich, and threonine-rich sequences. Mol Cell Biol. 1992;12:2396-2405.
2. Plutzky J, Neel BG, Rosenberg RD. Isolation of a Src Homology2-containing tyrosine phosphatase. Proc Natl Acad Sci U S A. 1992;89:1123-1127.
3. Yi T, Cleveland JL, Ihle JN. Protein tyrosine phosphatase containing SH2 domains: characterisation, preferential expression in hematopoietic cells and localisation to human chromosome 12p12-p13. Mol Cell Biol. 1992;12:836-846.
4. Green MC, Shultz LD. Motheaten, an immunodeficient mutant of the mouse, I: genetics and pathology. J Hered. 1975;66:250-258.
5. Shultz LD, Coman DR, Bailey CL, Beamer WG, Sidman CL. Viable motheaten, a new allele at the motheaten locus, 1: pathology. Am J Pathol. 1984;116:179-192.
6. Shultz LD, Rajan TV, Greiner DL. Severe defects in immunity and hematopoiesis caused by SHP-1 protein-tyrosine-phosphatase deficiency. Trends Biotechnol. 1997;15:302-307.
7. Zhang JY, Somani AK, Siminovitch KA. Roles of the SHP-1 tyrosine phosphatase in the negative regulation of cell signalling. Semin Immunol. 2000;12:361-378.
8. Zhang JY, Somani AK, Yuen D, Yang Y, Love PE, Siminovitch KA. Involvement of the SHP-1 tyrosine phosphatase in regulation of T cell selection. J Immunol. 1999;163:3012-3021.
9. Johnson KG, LeRoy FG, Borysiewicz LK, Matthews RJ. TCR signaling thresholds regulating T cell development and activation are dependent upon SHP-1. J Immunol. 1999;162:3802-3813.
10. Paling NRD, Welham MJ. The role of the protein tyrosine phosphatase SHP-1 in regulation of interleukin-3-induced survival, proliferation and signalling. Biochem J. 2002;368:885-894.
11. Dustin LB, Plas DR, Wong J, et al. Expression of dominant-negative Src-homology domain 2-containing protein tyrosine phosphase-1 results in increased Syk tyosine kinase activity and B cell activation. J Immunol. 1999;162:2717-2724.
12. Maeda A, Scharenberg AM, Tsukada S, Bolen J, Kinet JP, Kurosaki T. Paired immunoglobulin-like receptor B (PIR-B) inhibits BCR-induced activation of Syk and Btk by SHP-1. Oncogene. 1999;18:2291-2297.
13. Neel BG, Gu HH, Pao L. The 'Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signalling. Trends Biochem Sci. 2003;28:284-293.
14. McCoy KL, Chi E, Engel D, Rosse C, Clagett J. Abnormal in vitro proliferation of splenic mononuclear phagocytes from autoimmune motheaten mice. J Immunol. 1982;128:1797-1804.
15. McCoy KL, Engel D, Clagett J. Accelerated rate of mononuclear phagocyte production in vitro by splenocytes from autoimmune motheaten mice. Am J Pathol. 1983;112:18-26.
16. Shultz LD, Bailey CL, Coman DR. Hematopoietic stem-cell function in motheaten mice. Exp Hematol. 1983;11:667-680.
17. Van Zant G, Shultz L. Hematologic abnormalities of the immunodeficient mouse mutant, viable motheaten (Me-Nu). Exp Hematol. 1989;17:81-87.
18. Jiao HY, Yang WT, Berrada K, Tabrizi M, Shultz L, Yi TL. Macrophages from motheaten and viable motheaten mutant mice show increased proliferative responses to GM-CSF: detection of potential HCP substrates in GM-CSF signal transduction. Exp Hematol. 1997;25:592-600.
19. Tapley P, Shevde NK, Schweitzer PA, et al. Increased G-CSF responsiveness of bone marrow cells from hematopoietic cell phosphatase deficient viable motheaten mice. Exp Hematol. 1997;25:122-131.
20. Chen HE, Chang S, Trub T, Neel BG. Regulation of colony-stimulating factor 1 receptor signaling by the SH2 domain-containing tyrosine phosphatase SHPTP1. Mol Cell Biol. 1996;16:3685-3697.
21. Medlock ES, Goldschneider I, Greiner DL, Shultz L. Defective lymphopoiesis in the bone-marrow of moth-eaten (me/me) and viable moth-eaten (mev/mev) mutant mice, 2: description of a microenvironmental defect for the generation of terminal deoxynucleotidyltransferase-positive bone-marrow cells-invitro. J Immunol. 1987;138:3590-3597.
22. Greiner DL, Goldschneider I, Komschlies KL, Medlock ES, Bollum FJ, Shultz L. Defective lymphopoiesis in bone marrow of motheaten (me/me) and viable motheaten (mev/mev) mutant mice, I: analysis of development of prothymocytes, early B lineage cells and terminal deoxynucleotidyl transferase-positive cells. J Exp Med. 1986;164:1129-1144.
23. Yu CCK, Tsui HW, Ngan BY, Shulman MJ, Wu GE, Tsui FWL. B and T cells are not required for the viable motheaten phenotype. J Exp Med. 1996;183:371-380.
24. Koo GC, Manyak CL, Dasch J, Ellingsworth L, Shultz LD. Suppressive effects of monocytic cells and transforming growth factor beta on natural killer cell differentiation in autoimmune motheaten viable mutant mice. J Immunol. 1991;147:1194-1200.
25. Hayashi SI, Witte PL, Shultz LD, Kincade PW. Lymphohemopoiesis in culture is prevented by interaction with adherent bone-marrow cells from mutant viable motheaten mice. J Immunol. 1988;140:2139-2147.
26. Evans MJ, Kaufmann M. Establishment in culture of pluripotential cells from mouse embryos. Nature. 1981;292:154-156.
27. Martin GR. Isolation of a pluripotent cell line from early mouse embryos cultured in medium conditioned by teratocarcinoma stem cells. Proc Natl Acad Sci U S A. 1981;78:7634-7638.
28. Smith AG. Embryo-derived stem cells: of mice and men. Annu Rev Cell Dev Biol. 2001;17:435-462.
29. Wiles MV, Keller G. Multiple hematopoietic lineages develop from embryonic stem (ES) cells in culture. Development. 1991;111:259-267.
30. Keller G, Kennedy M, Papayannopoulou T, Wiles MV. Hematopoietic commitment during embryonic stem-cell differentiation in culture. Mol Cell Biol. 1993;13:473-486.
31. Keller GM. In-vitro differentiation of embryonic stem-cells. Curr Opin Cell Biol. 1995;7:862-869.
32. Smith AG, Hooper mL. Buffalo rat-liver cells produce a diffusible activity which inhibits the differentiation of murine embryonal carcinoma and embryonic stem-cells. Dev Biol. 1987;121:1-9.
33. Paling NRD, Wheadon H, Bone HK, Welham MJ. Regulation of embryonic stem cell self-renewal by phosphoinositide 3-kinase-dependent signalling. J Biol Chem. 2004;279:48063-48070.
34. Nakano T. In vitro development of hematopoietic system from mouse embryonic stem cells: a new approach for embryonic hematopoiesis. Int J Hematol. 1996;65:1-8.
35. Nakano T, Kodama H, Honjo T. Generation of lymphohematopoietic cells from embryonic stem-cells in culture. Science. 1994;265:1098-1101.
36. Craddock BL, Orchiston EA, Hinton HJ, Welham MJ. Dissociation of apoptosis from proliferation, protein kinase B activation, and BAD phosphorylation in interleukin-3-mediated phosphoinositide 3-kinase signaling. J Biol Chem. 1999;274:10633-10640.
37. Era T, Witte ON. Regulated expression of p210 Bcr-Abl during embryonic stem cell differentiation stimulates multipotential progenitor expansion and myeloid cell fate. Proc Natl Acad Sci U S A. 2000;97:1737-1742.
38. Craddock BL, Hobbs J, Edmead C, Welham MJ. Phosphoinoside 3-kinase-dependent regulation of IL-3-induced proliferation: involvement of mitogen-activated protein kinases, SHP2 and Gab2. J Biol Chem. 2001;276:24274-24283.
39. Welham MJ, Dechert U, Leslie KB, Jirik F, Schrader JW. Interleukin (IL)-3 and granulocyte/macrophage colony-stimulating factor, but not IL-4, induce tyrosine phosphorylation, activation, and association of SHPTP2 with Grb2 and phosphatidylinositol 3′-kinase. J Biol Chem. 1994;269:23764-23768.
40. Era T, Wong S, Witte ON. Analysis of Bcr-Abl function using an in vitro embryonic stem cell differentiation system. In: K. Turksen, ed. Embryonic Stem Cells: Methods and Protocols. Vol 185. Totowa, NJ: Humana Press; 2001, 83-95.
41. Kennedy M, Firpo M, Choi K, et al. A common precursor for primitive erythropoiesis and definitive haematopoiesis. Nature. 1997;386:488-493.
42. Neel BG, Plutzky J, Rosenberg RD, Freeman RM, Lorentz U, Lechleider RJ. Molecular cloning and characterisation of a subfamily of non-transmembrane protein tyrosine phophastases containing src-homolgy-2 (SH2) domains: advances in protein phosphatases. Vol 7: Leuven University Press; 1993:127-151.
43. Timms JF, Carlberg K, Gu HH, et al. Identification of major binding proteins and substrates for the SH2-containing protein tyrosine phosphatase SHP-1 in macrophages. Mol Cell Biol. 1998;18:3838-3850.
44. Niwa H, Miyazaki J, Smith AG. Quantitative expression of Oct-3/4 defines differentiation, dedifferentiation or self-renewal of ES cells. Nat Genet. 2000;24:372-376.
45. Lorenz U, Bergemann AD, Steinberg HN, et al. Genetic analysis reveals cell type-specific regulation of receptor tyrosine kinase c-Kit by the protein tyrosine phosphatase SHP1. J Exp Med. 1996;184:1111-1126.
46. Hara TK, Sakuma Y, Sakai S, Nagata M, Aoki F. Dynamic changes in the expression of protein tyrosine phosphatases during preimplantation mouse development: semi-quantification by real-time PCR. J Reprod Dev. 2003;49:323-328.
47. Yang WT, Tabrizi M, Yi TL. A bipartite NLS at the SHP-1C-terminus mediates cytokine-induced SHP-1 nuclear localization in cell growth control. Blood Cell Mol Dis. 2002;28:63-74.
48. Craggs G, Kellie S. A functional nuclear localisation sequence in the carboxyl domain of SHP-1. J Biol Chem. 2001;276:23719-23725.
49. Yang J, Liu LJ, He DD, et al. Crystal structure of human protein-tyrosine phosphatase SHP-1. J Biol Chem. 2003;278:6516-6520.